Robert W. Baird Raises Boston Scientific (NYSE:BSX) Price Target to $128.00

Key Points

• Robert W. Baird has raised the price target for Boston Scientific (NYSE: BSX) from $123.00 to $128.00, indicating a potential upside of 31.21% from the stock's previous close.
• Boston Scientific's recent quarterly earnings showed an EPS of $0.75, exceeding analysts' expectations of $0.72, and the company's revenue was reported at $5.06 billion, significantly above estimates.
• Multiple research firms have recently issued favorable ratings for Boston Scientific, with a consensus rating of "Buy" and an average target price of $120.50 among analysts.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective lifted by Robert W. Baird from $123.00 to $128.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical equipment provider's stock. Robert W. Baird's target price suggests a potential upside of 31.21% from the stock's previous close.

A number of other research firms also recently commented on BSX. Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. UBS Group upped their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Royal Bank Of Canada restated an "outperform" rating and issued a $125.00 target price on shares of Boston Scientific in a research report on Monday. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a research report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $120.50.

Boston Scientific Stock Up 0.5%

Shares of Boston Scientific stock opened at $97.55 on Wednesday. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a fifty day moving average price of $103.53 and a 200 day moving average price of $102.13. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $144.54 billion, a price-to-earnings ratio of 58.07, a price-to-earnings-growth ratio of 2.34 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,214 shares of company stock valued at $13,048,957 over the last three months. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares in the last quarter. State Street Corp boosted its position in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock valued at $7,002,258,000 after buying an additional 713,379 shares in the last quarter. Geode Capital Management LLC grew its stake in Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock worth $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $2,089,937,000. Finally, Invesco Ltd. increased its holdings in shares of Boston Scientific by 1.4% during the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.